Cytokinetics Offers Upbeat Data from Mid-Stage Trial of ALS drug

Cytokinetics reports interim phase II data of CK-2017357 in ALS patients. Daily administration of varying drug doses was reported to be sufficiently tolerated with dizziness being the most common side effect among the 24 study participants. Cytokinetics plans to launch a third phase II study that will focus on patients currently taking Rilutek.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail